AAPG · Ascentage Pharma Group Internat
$15.44
+3.48% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-23.9
Dividend yield
0.0%
Beta
0.66
Avg volume
0M
Employees
1K
Daily Change %
3.48%
5 Days Change
-2.93%
10 Days Change
-0.93%
30 Days Change
-4.24%
60 Days Change
-10.71%
Month to Day Change
-6.16%
Year to Day Change
-43.14%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AAPG
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
Citigroup
Buy$46.00
+197.9% vs priceJP Morgan
Overweight$33.00
+113.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-14 | Citigroup | Initiates | Buy | $0.00 → $46.00 |
| 2026-10-13 | Citizens | Initiates | Market Outperform | $0.00 → $35.00 |
| 2026-10-08 | JP Morgan | Maintains | Overweight | $46.00 → $33.00 |
| 2026-08-21 | BTIG | Reiterates | Buy | $48.00 |
| 2026-06-15 | BTIG | Reiterates | Buy | $48.00 |
| 2026-06-10 | B. Riley Securities | Initiates | Buy | $0.00 → $45.00 |
| 2026-04-13 | BTIG | Reiterates | Buy | $48.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 4.6% below the 50-day MA ($16.19).
- bearish: Price vs 200-day MA: Trading 24.6% below the 200-day MA ($20.48).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.12) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($14.55).
AAPG Price Chart
Loading chart for AAPG…
Fundamentals
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.